Researchers from the Department of Pediatric Gastroenterology and Nutrition of the UCC MUW, under the guidance of Professor Aleksandra Banaszkiewicz, developed a steroid drug for the local treatment of inflammatory lesions located in the esophagus, stomach or duodenum. The drug will be administered in the form of a very thick syrup, so that its contact with the mucous membrane of the occupied digestive tract is as long as possible.
The patients will take the drug orally for 8 weeks. After this time, the researchers will assess the safety and tolerance of the treatment and the percentage of patients who have received the desired effect.
Crohn's disease is an inflammatory bowel disease, a serious, life-long disease. It belongs to the autoimmune diseases which etiology has not been fully explained. The inflammatory changes accompanying the disease can affect any section of the digestive tract from the oral cavity to the rectum.